Contribution of Genetic Polymorphisms to the Abuse Liability of Oxycodone

The proposed study examined the prevalence of various genetic polymorphisms thought to be involved in opioid abuse among current heroin users. In addition to providing blood samples for genetics analysis, participants completed a number of questionnaires that allowed us to learn detailed information about their current and history of opioid drug use.

• Study Design:
  • Case Set
• Study Type:
  • Case Set
• dbGaP estimated ancestry using GRAF-pop
• Total number of consented subjects: 193
• Subject Sample Telemetry Report (SSTR)

Inclusion:

1. Male or female participant aged 21 to 55 years.
2. Volunteers meeting DSM IV criteria for heroin abuse or dependence who endorse heroin as their drug of choice.
3. Not currently seeking treatment for opioid abuse.
4. In otherwise good health.
5. Able to give written informed consent to participate.
6. Able to fluently speak and read English.

Exclusion:

1. Blood transfusion within the last 4 weeks.
2. Active severe psychiatric disorder that might interfere with participation or make participation hazardous.

• Primary Phenotype: Heroin Dependence

• OPRD1
• OPRK1
• OPRM1

• BioProject
• PubMed
• BioSample
• MeSH
• Gene
• PMC

• Principal Investigator
  • Jermaine Jones, PhD. Columbia University Medical Center, New York, NY, USA.
• Funding Source
  • K01DA030446. National Institutes on Drug Abuse, Baltimore, MD, USA.